India, Nov. 16 -- Eloxx Pharmaceuticals, Inc. (ELOX) reported Monday a wider third-quarter net loss as operating expenses increased.
Company Profile
Eloxx develops small-molecule therapies for diseases caused by nonsense mutations, focusing on rare kidney disorders.
Third-Quarter 2026 Financial Results
Net loss widened to $5.54 million from $0.35 million a year earlier. Diluted loss per share narrowed to $0.49 from $0.58.
Research and development (R&D) expenses reached $4.03 million, compared with a $0.25 million credit a year earlier, reflecting higher EXACT trial and personnel costs. Prior-year expenses benefited from vendor settlements.
General and administrative expenses rose to $1.93 million from $0.54 million, reflecting higher ...